Clinical Trial Update: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CPI-613 for refractory or relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Status: WITHDRAWN